Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092212 | 1.00 | CYP2C19 (0.47) | CYP2C19SMN1; SMN2HIF1ABLMNOS1 | |
| SCHEMBL4092217 | 1.00 | CYP2C19 (0.47) | CYP2C19SMN1; SMN2HIF1ABLMNOS1 | |
| Hydrochloric Acid SCHEMBL4106419 | 0.98 | NOS1 (0.46) | CYP2C19SMN1; SMN2HIF1ABLMNOS1 | |
| SCHEMBL13696271 | 0.88 | CYP2C19 (0.46) | CYP2C19SMN1; SMN2HIF1ACYP1A2CYP3A4 | |
| SCHEMBL4097392 | 0.88 | CYP2C19 (0.46) | CYP2C19SMN1; SMN2HIF1ANOS1NOS2 | |
| SCHEMBL4105009 | 0.88 | CYP2C19 (0.46) | CYP2C19SMN1; SMN2HIF1ANOS1NOS2 | |
| SCHEMBL4097397 | 0.88 | CYP2C19 (0.46) | CYP2C19SMN1; SMN2HIF1ANOS1NOS2 | |
| Hydrochloric Acid SCHEMBL4099430 | 0.87 | CYP2C19 (0.42) | CYP2C19SMN1; SMN2HIF1ABLMNOS1 | |
| Hydrochloric Acid SCHEMBL4099595 | 0.87 | CYP2C19 (0.45) | CYP2C19SMN1; SMN2HIF1ANOS1NOS2 | |
| Hydrochloric Acid SCHEMBL4099598 | 0.87 | CYP2C19 (0.45) | CYP2C19SMN1; SMN2HIF1ANOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3006449-B1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE ALPHA-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[C,E]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9695112-B2 | Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid | HAMARI CHEMICALS, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695112-B2 | Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid | HAMARI CHEMICALS, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695112-B2 | Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid | HAMARI CHEMICALS, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| EP-3006449-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE -AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID | Hamari Chemicals, Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-3006449-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE -AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID | Hamari Chemicals, Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-105189524-A | Method for synthesizing optically active alpha-amino acid using chiral metal complex comprising axially chiral n-(2-acylaryl)-2-[5,7-dihydro-6h-dibenzo[c,e]azepin-6-yl]acetamide compound and amino acid | HAMARI CHEMICALS LTD | 2015-12-23 | — | — | CN | disclosed |
| US-20090221640-A1 | Novel Crystal Modifications | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221640-A1 | Novel Crystal Modifications | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221640-A1 | Novel Crystal Modifications | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-2064202-A2 | A NEW CRYSTALLINE FORM G OF (5S)-5-[4-(5-CHLORO-PYRIDIN-2-YLOXY)-PIPERIDINE-1-SULFONYL-METHYL]-5-METHYL-IMIDAZOLIDINE-2,4-DIONE (I) AND INTERMEDIATES THEREOF. | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2007106022-A2 | A NEW CRYSTALLINE FORM G OF (5S) -5- [4- (5-CHLORO-PYRIDIN-2- YLOXY) -PIPERIDINE-1-SULFONYLMETHYL] - 5 -METHYL -IMIDAZOLIDINE - 2,4-DIONE (I) AND INTERMEDIATES THEREOF. | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106022-A2 | A NEW CRYSTALLINE FORM G OF (5S) -5- [4- (5-CHLORO-PYRIDIN-2- YLOXY) -PIPERIDINE-1-SULFONYLMETHYL] - 5 -METHYL -IMIDAZOLIDINE - 2,4-DIONE (I) AND INTERMEDIATES THEREOF. | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | AADAT, ALDH7A1, BCAT1 | CYP2C19 1397/4885SMN1; SMN2 3709/4885HIF1A 3721/4885 |
| US-20090221640-A1 | Novel Crystal Modifications | PTMS, NT5C, CDK5 | CYP2C19 872/4885SMN1; SMN2 4216/4885HIF1A 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.